Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of Paroxetine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Objectives:
1. To determine whether paroxetine can prevent major depression in patients with hepatitis
C (HCV) who are receiving pegylated-interferon (Peg-IFN).
2. To determine whether paroxetine can prevent subsyndromal increases in depression and
anxiety in patients with HCV who are receiving Peg-IFN.
3. To determine whether paroxetine can prevent a significant change in the health related
quality of life in patients with HCV who are receiving Peg-IFN.
4. To determine whether paroxetine improves compliance with Peg-IFN therapy for HCV.
5. To determine whether paroxetine enables patients to complete Peg-IFN therapy for HCV who
might otherwise require a dose reduction or discontinuation because of neuropsychiatric
side effects.